 EAGAN, Minn., Jan. 14, 2021 GLOBE NEWSWIRE -- Predictive Oncology NASDAQ: POAI, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New York City and the other in Boston, Massachusetts. Both the New York City and the Boston orders are repeat orders and are focused on culturing ovarian cancer cells with specific research goals. One additional order came from a private company doing research on ovarian cancer. 